| Predicate |
Object |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-437 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-437
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-04 |
| filingDate |
2017-06-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2022-11-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2022-11-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-102472198-B1 |
| titleOfInvention |
Azabenzimidazole derivatives as PI3K beta inhibitors |
| abstract |
The present invention relates to Formula I: [Formula I] to the azabenzimidazole derivatives of, wherein the parameters have the meanings defined in the claims. The compounds according to the present invention are useful as pI3Kβ inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as active ingredients and to the use of said compounds as medicaments. |
| priorityDate |
2016-06-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |